Description: Managed strategies as underlying investments in VA/FIA products have seen spectacular growth since the financial crisis. The speakers of these sessions will share their views on the development of this market and what is expected to unfold over the next 12 months in regard to the next generation of products and fund-based strategies.

Description: In this session 36OF of the New York Annual Meeting panelists discuss and compare the risk management practices used by insurers and by banks. From the Record of the Society of Actuaries, Vol. 24, No. 3.

Description: Presenter discusses some techniques for minimizing and controlling the damage to defined-benefit pension surpluses caused by market forces. From the Record of the Society of Actuaries, Vol. 25, No. 2.

Description: Insurance is a technically demanding, risk-based, capital intensive business. It is therefore not surprising that the industry is fertile ground for the development of technical models used to measure and price risk and manage capital. This session presents the forces which have significantly influenced the evolution of risk and capital management techniques and organization in the insurance industry, including regulatory changes, financial market instability, enlightened self-interest and ultimately a focus on shareholder value creation. Combining over 20 years in the industry in risk and finance roles with a rigorous academic approach, the presenter will provide insights into the most important business questions which insurers face today and the technical tools and frameworks used to answer them.

Description: This discussion looks at the problems considered in drafting war-aviation clauses, plans for mitigating catastrophe hazard with respect to policyholders in the event of a major war, and steps which may be taken to minimize war disruptions of life insurance home office operations.

Description: The presenters describe the process payers and employers can use to evaluate emerging medical device technologies, recent or pending FDA submissions for prescription drugs and experimental treatments that impact patient care, resource utilization and health care expenditures. Learn the process of identifying and selecting impactful treatments (Horizon Scanning) and quantifying the financial cost of new technologies before they arrive in the market. These workflows can be leveraged by actuaries, healthcare economists, clinicians and pharmacists from a payer (Commercial and Medicare) and employer perspective for self-funded plans. Walk through sample models that illustrate how costs for emerging technologies and treatments can be modeled.

Description: Panel discusses securitization as a popular method for improving returns and clearing up balance sheets. From the Record of the Society of Actuaries, Vol. 23, No. 3., Session 74 PD of the Washington Annual Meeting

Description: This session explores where financial engineering is applied, who is “leading the charge,” and what are the current and future roles of actuaries. From the Record of the Society of Actuaries, Volume 27, No. 2, Session 55PD of the Toronto Spring Meeting.

Description: From the Record 1977 Vol. 3, No. 1, this presentation is from a concurrent session at the Society of Actuaries 1977 Regional Meeting, held in Atlanta March 31-April 1. The presenters at this session discuss the sources of funds for stock life insurance companies, including debt, capital, policyholders, and coinsurance, and the prioritization of the use of funds. “Enterprise risk exposure and management” and policyholder vs. shareholder dividend philosophy are additional topics.

Description: There is no “industry standard” approach to managing the vega (volatility) risk inherent in Variable Annuity Guarantees, Fixed Indexed Annuities and other equity-linked obligations. In this session, we will introduce and analyze a range of reinsurance solutions, including full vega risk retention, full vega risk transfer and more sophisticated or custom structures that split the vega risk between the insurer and the reinsurer in various ways. We will also explore other approaches in bespoke risk coverage and show the impact of different assumptions on a generic “VA Guarantee Cost Estimate” that has been developed by Munich Re.